<?xml version='1.0' encoding='utf-8'?>
<document id="18445994"><sentence text="Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5."><entity charOffset="20-30" id="DDI-PubMed.18445994.s1.e0" text="tacrolimus" /><entity charOffset="35-47" id="DDI-PubMed.18445994.s1.e1" text="lansoprazole" /><entity charOffset="57-68" id="DDI-PubMed.18445994.s1.e2" text="rabeprazole" /><pair ddi="false" e1="DDI-PubMed.18445994.s1.e0" e2="DDI-PubMed.18445994.s1.e0" /><pair ddi="false" e1="DDI-PubMed.18445994.s1.e0" e2="DDI-PubMed.18445994.s1.e1" /><pair ddi="false" e1="DDI-PubMed.18445994.s1.e0" e2="DDI-PubMed.18445994.s1.e2" /><pair ddi="false" e1="DDI-PubMed.18445994.s1.e1" e2="DDI-PubMed.18445994.s1.e1" /><pair ddi="false" e1="DDI-PubMed.18445994.s1.e1" e2="DDI-PubMed.18445994.s1.e2" /></sentence><sentence text="We report different effects of administration of proton pump inhibitors on tacrolimus blood concentration in two living-donor liver transplant patients" /><sentence text=" In case 1, a 51-year-old man with liver cirrhosis due to hepatitis C virus underwent living-donor liver transplantation, and tacrolimus was orally administered"><entity charOffset="126-136" id="DDI-PubMed.18445994.s3.e0" text="tacrolimus" /></sentence><sentence text=" Omeprazole (40 mg/day) was introduced intravenously between postoperative days 5 and 6, and oral lansoprazole (30 mg/day) was introduced from day 6, leading to an increase in the concentration/dose ratio of tacrolimus from day 10"><entity charOffset="1-11" id="DDI-PubMed.18445994.s4.e0" text="Omeprazole" /><entity charOffset="98-110" id="DDI-PubMed.18445994.s4.e1" text="lansoprazole" /><entity charOffset="208-218" id="DDI-PubMed.18445994.s4.e2" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.18445994.s4.e0" e2="DDI-PubMed.18445994.s4.e0" /><pair ddi="false" e1="DDI-PubMed.18445994.s4.e0" e2="DDI-PubMed.18445994.s4.e1" /><pair ddi="false" e1="DDI-PubMed.18445994.s4.e0" e2="DDI-PubMed.18445994.s4.e2" /><pair ddi="false" e1="DDI-PubMed.18445994.s4.e1" e2="DDI-PubMed.18445994.s4.e1" /><pair ddi="false" e1="DDI-PubMed.18445994.s4.e1" e2="DDI-PubMed.18445994.s4.e2" /></sentence><sentence text=" In case 2, a 41-year-old living-donor liver transplant woman received tacrolimus, and co-administered with omeprazole (40 mg/day) intravenously during 7 days immediately after surgery"><entity charOffset="71-81" id="DDI-PubMed.18445994.s5.e0" text="tacrolimus" /><entity charOffset="108-118" id="DDI-PubMed.18445994.s5.e1" text="omeprazole" /><pair ddi="false" e1="DDI-PubMed.18445994.s5.e0" e2="DDI-PubMed.18445994.s5.e0" /><pair ddi="false" e1="DDI-PubMed.18445994.s5.e0" e2="DDI-PubMed.18445994.s5.e1" /></sentence><sentence text=" During this period, trough concentration of tacrolimus was high, but the concentration/dose ratio of tacrolimus was gradually decreasing with time"><entity charOffset="45-55" id="DDI-PubMed.18445994.s6.e0" text="tacrolimus" /><entity charOffset="102-112" id="DDI-PubMed.18445994.s6.e1" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.18445994.s6.e0" e2="DDI-PubMed.18445994.s6.e0" /><pair ddi="false" e1="DDI-PubMed.18445994.s6.e0" e2="DDI-PubMed.18445994.s6.e1" /></sentence><sentence text=" Switched to rabeprazole (10 mg/day) orally on the postoperative 8th day, the concentration/dose ratio of tacrolimus remained low, indicating little drug-drug interaction between tacrolimus and rabeprazole"><entity charOffset="13-24" id="DDI-PubMed.18445994.s7.e0" text="rabeprazole" /><entity charOffset="106-116" id="DDI-PubMed.18445994.s7.e1" text="tacrolimus" /><entity charOffset="179-189" id="DDI-PubMed.18445994.s7.e2" text="tacrolimus" /><entity charOffset="194-205" id="DDI-PubMed.18445994.s7.e3" text="rabeprazole" /><pair ddi="false" e1="DDI-PubMed.18445994.s7.e0" e2="DDI-PubMed.18445994.s7.e0" /><pair ddi="false" e1="DDI-PubMed.18445994.s7.e0" e2="DDI-PubMed.18445994.s7.e1" /><pair ddi="false" e1="DDI-PubMed.18445994.s7.e0" e2="DDI-PubMed.18445994.s7.e2" /><pair ddi="false" e1="DDI-PubMed.18445994.s7.e0" e2="DDI-PubMed.18445994.s7.e3" /><pair ddi="false" e1="DDI-PubMed.18445994.s7.e1" e2="DDI-PubMed.18445994.s7.e1" /><pair ddi="false" e1="DDI-PubMed.18445994.s7.e1" e2="DDI-PubMed.18445994.s7.e2" /><pair ddi="false" e1="DDI-PubMed.18445994.s7.e1" e2="DDI-PubMed.18445994.s7.e3" /><pair ddi="false" e1="DDI-PubMed.18445994.s7.e2" e2="DDI-PubMed.18445994.s7.e2" /><pair ddi="false" e1="DDI-PubMed.18445994.s7.e2" e2="DDI-PubMed.18445994.s7.e3" /></sentence><sentence text=" In both cases, the genotypes of CYP2C19 and CYP3A5 were defective both in the graft liver and in the native intestine" /><sentence text=" A drug-drug interaction between rabeprazole and tacrolimus was not observed in this case study presented, suggesting that this combination could be safely used in tacrolimus therapy after liver transplantation"><entity charOffset="33-44" id="DDI-PubMed.18445994.s9.e0" text="rabeprazole" /><entity charOffset="49-59" id="DDI-PubMed.18445994.s9.e1" text="tacrolimus" /><entity charOffset="164-174" id="DDI-PubMed.18445994.s9.e2" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.18445994.s9.e0" e2="DDI-PubMed.18445994.s9.e0" /><pair ddi="false" e1="DDI-PubMed.18445994.s9.e0" e2="DDI-PubMed.18445994.s9.e1" /><pair ddi="false" e1="DDI-PubMed.18445994.s9.e0" e2="DDI-PubMed.18445994.s9.e2" /><pair ddi="false" e1="DDI-PubMed.18445994.s9.e1" e2="DDI-PubMed.18445994.s9.e1" /><pair ddi="false" e1="DDI-PubMed.18445994.s9.e1" e2="DDI-PubMed.18445994.s9.e2" /></sentence><sentence text="" /></document>